The city of New York, New York, currently has 4 active clinical trials seeking participants for Skin Cancer research studies.
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Recruiting
We seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. We will execute this by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, instruct subjects to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Bruce Robinson, MD, New York, New York
Conditions: Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
Brodalumab in the Treatment of Immune-Related Adverse Events
Recruiting
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: New York University Clinical Cancer Center, New York, New York +1 locations
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Recruiting
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer